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ARTICLE
Immune-mediated genetic pathways resulting
in pulmonary function impairment increase lung
cancer susceptibility
Linda Kachuri et al.#
Impaired lung function is often caused by cigarette smoking, making it challenging to dis-
entangle its role in lung cancer susceptibility. Investigation of the shared genetic basis of
these phenotypes in the UK Biobank and International Lung Cancer Consortium (29,266
cases, 56,450 controls) shows that lung cancer is genetically correlated with reduced forced
expiratory volume in one second (FEV1: rg= 0.098, p= 2.3 × 10−8) and the ratio of FEV1 to
forced vital capacity (FEV1/FVC: rg= 0.137, p= 2.0 × 10−12). Mendelian randomization
analyses demonstrate that reduced FEV1 increases squamous cell carcinoma risk (odds ratio
(OR)= 1.51, 95% confidence intervals: 1.21–1.88), while reduced FEV1/FVC increases the risk
of adenocarcinoma (OR= 1.17, 1.01–1.35) and lung cancer in never smokers (OR= 1.56,
1.05–2.30). These findings support a causal role of pulmonary impairment in lung cancer
etiology. Integrative analyses reveal that pulmonary function instruments, including 73 novel
variants, influence lung tissue gene expression and implicate immune-related pathways in
mediating the observed effects on lung carcinogenesis.
https://doi.org/10.1038/s41467-019-13855-2 OPEN
#A full list of authors and their affiliations appears at the end of the paper.
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Lung cancer is the most commonly diagnosed cancerworldwide and the leading cause of cancer mortality1.Although tobacco smoking remains the predominant risk
factor for lung cancer, clinical observations and epidemiological
studies have consistently shown that individuals with airflow
limitation, particularly those with chronic obstructive pulmonary
disease (COPD), have a significantly higher risk of developing
lung cancer2–7. Several lines of evidence suggest that biological
processes resulting in pulmonary impairment warrant con-
sideration as independent lung cancer risk factors, including
observations that previous lung diseases influence lung cancer
risk independently of tobacco use6,8–10, and overlap in genetic
susceptibility loci for lung cancer and chronic obstructive pul-
monary disease (COPD) on 4q24 (FAM13A), 4q31 (HHIP), 5q.32
(HTR4), the 6p21 region, and 15q25 (CHRNA3/CHRNA5)11–14.
Inflammation and oxidative stress have been proposed as key
mechanisms promoting lung carcinogenesis in individuals affec-
ted by COPD or other non-neoplastic lung pathologies9,11,15.
Despite an accumulation of observational findings, previous
epidemiological studies have been unable to conclusively establish
a causal link between indicators of impaired pulmonary function
and lung cancer risk due to the interrelated nature of these
conditions7. Lung cancer and obstructive pulmonary disease
share multiple etiological factors, such as cigarette smoking,
occupational inhalation hazards, and air pollution, and 50–70% of
lung cancer patients present with co-existing COPD or airflow
obstruction6. Furthermore, reverse causality remains a concern
since pulmonary symptoms may be early manifestations of lung
cancer or acquired lung diseases in patients whose immune sys-
tem has already been compromised by undiagnosed cancer.
Disentangling the role of pulmonary impairment in lung cancer
development is important from an etiological perspective, for
refining disease susceptibility mechanisms, and for informing pre-
cision prevention and risk stratification strategies. In this study we
comprehensively assess the shared genetic basis of impaired lung
function and lung cancer risk by conducting genome-wide asso-
ciation analyses in the UK Biobank cohort to identify genetic
determinants of three pulmonary phenotypes, forced expiratory
volume in 1s (FEV1), forced vital capacity (FVC), and FEV1/FVC.
We examine the genetic correlation between pulmonary function
phenotypes and lung cancer, followed by Mendelian randomization
(MR) using novel genetic instruments to formally test the causal
relevance of impaired pulmonary function, using the largest avail-
able dataset of 29,266 lung cancer cases and 56,450 controls from
the OncoArray lung cancer collaboration16.
Results
Heritability and genetic correlation. Array-based, or narrow-
sense, heritability (hg) estimates for all lung phenotypes were
obtained using LD score regression17 based on summary statistics
from our GWAS of the UKB cohort (n= 372,750 for FEV1, n=
370,638 for FVC, n= 368,817 for FEV1/FVC; Supplementary
Fig. 1) are presented in Table 1. Heritability estimates based on
UKB-specific LD scores (n= 7,567,036 variants) were consistently
lower but more precise than those based on the 1000Genomes
(1000G) Phase 3 reference population (n= 1,095,408 variants). For
FEV1, hg= 0.163 (SE= 0.006) and hg= 0.201 (SE= 0.008), based
on UKB and 1000 G LD scores, respectively. Estimates for FVC
were hg= 0.175 (SE= 0.007) and hg= 0.214 (SE= 0.010). Herit-
ability was lower for FEV1/FVC: hg= 0.128 (SE= 0.006) and 0.157
(SE= 0.010), based on internal and 1000 G reference panels,
respectively. For all phenotypes, hg did not differ by smoking status
and estimates were not affected by excluding the major histo-
compatibility complex (MHC) region.
Partitioning heritability by functional annotation identified
large and statistically significant (p < 8.5 × 10−4) enrichments for
multiple categories (Fig. 1; Supplementary Tables 1–3). A total of
35 categories, corresponding to 22 distinct annotations, were
significantly enriched for all three pulmonary phenotypes,
including annotations that were not previously reported18. Large
enrichment, defined as the proportion of heritability accounted
for by a specific category relative to the proportion of SNPs in
that category, was observed for elements conserved in pri-
mates19,20 (17.6% of SNPs, 54.7–58.5% of hg), McVicker back-
ground selection statistic21,22 (17.8% of SNPs, 22.6–25.1% of hg),
flanking bivalent transcription starting sites (TSS)/enhancers
from Roadmap20,23 (1.4% of SNPs, 11.1–13.2% of hg), and super
enhancers (16.7% of SNPs, 33.9–38.6% of hg). We also replicated
previously reported significant enrichments for histone methyla-
tion and acetylation marks H3K4me1, H3K9Ac, and
H3K27Ac18,24.
Substantial genetic correlation was observed for pulmonary
phenotypes with body composition and smoking traits, mirroring
phenotypic correlations in epidemiologic studies (Fig. 2). Large
positive correlations with height were observed for FEV1 (rg=
0.568, p= 2.5 × 10−567) and FVC (rg= 0.652, p= 1.8 × 10−864).
Higher adiposity was negatively correlated with FEV1 (BMI:
rg=−0.216, p= 4.2 × 10−74; percent body fat: rg=−0.221, p=
1.7 × 10−66), FVC (BMI: rg=−0.262, p= 1.6 × 10−114; percent
body fat: rg=−0.254, p= 1.2 × 10−88). Smoking status (ever vs.
never) was significantly correlated with all lung function pheno-
types (FEV1 rg=−0.221, p= 8.1 × 10−78; FVC rg=−0.091, 1.0 ×
10−16; FEV1/FVC rg=−0.360, p= 7.5 × 10−130). Cigarette pack-
years and impaired lung function in smokers were also significantly
genetically correlated with FEV1 (rg=−0.287 p= 1.1 × 10−35),
FVC (rg=−0.253, p= 1.9 × 10−30), and FEV1/FVC (rg=−0.108,
p= 3.0 × 10−4). As a positive control, we verified that FEV1 and
FVC were genetically correlated with each other (rg= 0.922)
and with FEV1/FVC (FEV1: rg= 0.232, p= 4.1 × 10−32; FVC:
rg=−0.167, p= 1.0 × 10−19).
Genetic correlations between lung function phenotypes and lung
cancer are presented in Fig. 3. For simplicity of interpretation
coefficients were rescaled to represent genetic correlation with
impaired (decreasing) lung function. Impaired FEV1 was positively
correlated with lung cancer overall (rg= 0.098, p= 2.3 × 10−8),
squamous cell carcinoma (rg= 0.137, p= 7.6 × 10−9), and lung
cancer in smokers (rg= 0.140, p= 1.2 × 10−7). Genetic correlations
were attenuated for adenocarcinoma histology (rg= 0.041, p=
0.044) and null for never smokers (rg=−0.002, p= 0.96). A similar
pattern of associations was observed for FVC. Reduced FEV1/
FVC was positively correlated with all lung cancer subgroups
(overall: rg= 0.137, p= 2.0 × 10−12; squamous carcinoma: rg=
0.137, p= 4.3 × 10−8; adenocarcinoma: rg= 0.125, p= 7.2 × 10−9;
smokers: rg= 0.185, p= 1.4 × 10−10), except for never smokers
(rg= 0.031, p= 0.51).
Exploring the functional underpinnings of these genetic
correlations revealed three functional categories that were
significantly enriched for lung cancer (Supplementary Table 4),
and have not been previously reported25. All these categories were
also significantly enriched for pulmonary traits. CpG dinucleotide
content22 included only 1% of SNPs, but had a strong enrichment
signal for lung cancer (p= 2.1 × 10−7), FEV1 (p= 7.7 × 10−24),
FVC (p= 2.3 × 10−23, and FEV1/FVC (p= 3.8 × 10−17). Other
shared features included background selection (lung cancer: p=
1.0 × 10−6, FEV1: p= 1.9 × 10−20, FVC: p= 6.9 × 10−23, FEV1/
FVC: p= 1.5 × 10−15) and super enhancers (lung cancer: p=
4.4 × 10−6, FEV1: p= 3.4 × 10−24, FVC: p= 5.1 × 10−20, FEV1/
FVC: p= 9.6 × 10−22).
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Genome-wide association analysis for instrument develop-
ment. Based on the results of our GWAS in the UK Biobank, we
identified 207 independent instruments for FEV1 (P < 5 × 10−8,
replication P < 0.05; LD r2 < 0.05 within 10,000 kb), 162 for FVC,
and 297 for FEV1/FVC. We confirmed that our findings were not
affected by spirometry performance quality, with a nearly perfect
correlation between effect sizes (R2= 0.995, p= 2.5 × 10−196) in
the main discovery analysis and after excluding individuals with
potential blow acceptability issues (Field 3061 ≠ 0; n= 60,299).
After applying these variants to the lung cancer OncoArray
dataset and selecting LD proxies (r2 > 0.90) for unavailable var-
iants, the final set of instruments consisted of 193 variants for
FEV1, 144 for FVC, and 264 SNPs for FEV1/FVC (Supplementary
Data 1–3), for a total of 601 instruments. The proportion of trait
variation accounted for by each set of instruments was estimated
in the UKB replication sample consisting of over 110,00 indivi-
duals (Supplementary Fig. 1), and corresponded to 3.13% for
FEV1, 2.27% for FVC, and 5.83% for FEV1/FVC. We also
developed instruments specifically for never smokers based on a
separate GWAS of this population, which yielded 76 instruments
for FEV1, 112 for FEV1/FVC, and 57 for FVC, accounting for
2.06%, 4.21%, and 1.36% of phenotype variation, respectively
(Supplementary Data 4–6).
After removing overlapping instruments between pulmonary
phenotypes and LD-filtering (r2 < 0.05) across the three traits, 447
of the 601 variants were associated with at least one of FEV1,
FVC, or FEV1/FVC (P < 5 × 10−8, replication P < 0.05). We
compared these 447 independent variants to the 279 lung
function variants recently reported by Shrine et al.18 based on
an analysis of the UK Biobank and SpiroMeta consortium, by
performing clumping with respect to these index variants (LD
r2 < 0.05 within 10,000 kb). Our set of instruments included an
additional 73 independent variants, 69 outside the MHC region
(Supplementary Table 5), that achieved replication at the
Bonferroni-corrected threshold for each trait (maximum replica-
tion P= 2.0 × 10−4).
Our instruments included additional independent signals in
known lung function loci and variants in genes newly linked
to lung function, such as HORMAD2 at 22q12.1 (rs6006399:
PFEV1= 1.9 × 10−18), which is involved in synapsis surveillance
in meiotic prophase, and RIPOR1 at 16q22.1 (rs7196853:
PFEV1/FVC= 1.3 × 10−16), which plays a role in cell polarity and
directional migration. Several new variants further support the
importance of the tumor growth factor beta (TGF-β) signaling
pathway, including CRIM1 (rs1179500: PFEV1/FVC= 3.6 × 10−17)
and FGF18 (rs11745375: PFEV1/FVC= 1.6 × 10−11). Another novel
gene, PIEZO1 (rs750739: PFEV1= 1.8 × 10−10), encodes a
mechano-sensory ion channel, supports adaptation to stretch of
the lung epithelium and endothelium, and promotes repair after
alveolar injury26,27. In never smokers a signal was identified at
6q15 in BACH2 (rs58453446: PFEV1/FVC-nvsmk= 8.9 × 10−10), a
gene required for pulmonary surfactant homeostasis. Last, two
lung function variants mapped to genes somatically mutated in
lung cancer: EML4 (rs12466981: PFEV1/FVC= 2.7 × 10−14) and
BRAF (rs13227429: PFVC= 5.6 × 10−9).
Mendelian randomization. The causal relevance of impaired
pulmonary function was investigated by applying genetic instru-
ments developed in the UK Biobank to the OncoArray lung cancer
dataset, comprised of 29,266 lung cancer cases and 56,450 controls
(Supplementary Table 6). Primary analyses were based on the
maximum likelihood (ML) and inverse variance weighted (IVW)
multiplicative random-effects estimators28,29. Sensitivity analyses
were conducted using the weighted median (WM) and robust
adjusted profile score (RAPS) estimators30,31. A genetically pre-
dicted decrease in FEV1 was significantly associated with increased
risk of lung cancer overall (ORML= 1.28, 95% CI: 1.12–1.47, p=
3.4 × 10−4) and squamous carcinoma (ORML= 2.04, 1.64–2.54, p=
1.2 × 10−10), but not adenocarcinoma (ORML= 0.99, 0.83–1.19,
p= 0.96) (Fig. 4; Supplementary Table 7). The association with lung
cancer was not significant across all estimators (ORWM= 1.06, p=
0.57; ORRAPS= 1.13, p= 0.26). There was no evidence of directional
pleiotropy based on the MR Egger intercept test (β0 Egger ≠ 0, p <
0.05), but significant heterogeneity among SNP-specific causal effect
estimates was observed, which may be indicative of balanced hor-
izontal pleiotropy (lung cancer: PQ= 2.1 × 10−41; adenocarcinoma:
PQ= 3.4 × 10−9; squamous carcinoma: PQ= 1.1 × 10−30). After
excluding outlier variants contributing to this heterogeneity, 36 for
lung cancer and 34 for squamous carcinoma, the association with
FEV1 diminished for both phenotypes (lung cancer: ORML=
ORIVW= 1.12, p= 0.13), but remained statistically significant for
squamous carcinoma (ORIVW= 1.51, 1.21–1.88, p= 2.2 × 10−4),
with comparable effects observed using other estimators (ORML=
1.50, p= 6.7 × 10−4; ORRAPS= 1.48, p= 1.7 × 10−3; ORWM=
1.44, p= 0.040).
Genetic predisposition to reduced FVC was inconsistently
associated with squamous carcinoma risk (ORML= 1.68, p=
1.8 × 10−4; ORWM= 1.19, p= 0.38). Effects became attenuated
and more similar after removing outliers (ORML= 1.27, p=
0.10; ORRAPS= 1.25, p= 0.14) (Fig. 4; Supplementary Table 8).
A genetically predicted 10% decrease in FEV1/FVC was
associated with an elevated risk of lung cancer in some models
(ORML= 1.18, 1.07–1.31, p= 1.6 × 10−3), but not others
(ORWM= 1.10, p= 0.30; ORRAPS= 1.11, p= 0.14) (Fig. 4;
Supplementary Table 9). The association with squamous
carcinoma was also inconsistent across estimators. After
removing outliers contributing to significant effect heterogene-
ity (lung cancer: PQ= 1.2 × 10−28; adenocarcinoma: PQ= 3.4 ×
10−9; squamous carcinoma: PQ= 5.3 × 10−15), the association
Table 1 Array-based heritability for FEV1, FVC, and FEV1/FVC.
FEV1 FVC FEV1/FVC
UKB LD scores hg (SE) hg (SE) hg (SE)
Overall 0.163 (0.006) 0.175 (0.007) 0.128 (0.006)
Never smokers 0.163 (0.007) 0.169 (0.007) 0.126 (0.008)
Smokers 0.159 (0.007) 0.172 (0.009) 0.129 (0.008)
Overall no MHC 0.162 (0.006) 0.175 (0.007) 0.125 (0.006)
1000G LD scores
Overall 0.201 (0.008) 0.214 (0.010) 0.157 (0.010)
Never smokers 0.209 (0.010) 0.215 (0.011) 0.159 (0.011)
Smokers 0.208 (0.010) 0.221 (0.011) 0.166 (0.010)
Estimates were obtained using LD score regression applied to genome-wide summary statistics from the UK Biobank (UKB). Two types of LD scores were used: LD scores estimated using UK Biobank
(internal reference population) and pre-computed LD scores based on the 1000 Genomes Phase 3 reference population
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Fig. 1 Functional partitioning of array-based heritability for each pulmonary function phenotype. a The magnitude of category-specific enrichment and
corresponding −log10(p-value) for 22 distinct functional annotations that were significantly enriched for all three phenotypes (FEV1, FVC, FEV1/FVC). b The
proportion of heritability, Pr(hg), accounted for by each functional annotation with corresponding standard errors. Functional annotation categories are not
mutually exclusive.
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with adenocarcinoma strengthened (ORML= 1.17, 1.01–1.35;
ORRAPS= 1.18, 1.02–1.38), while associations for lung cancer
and squamous carcinoma became attenuated.
We examined the cancer risk in never smokers, by applying
genetic instruments developed specifically in this population, to
2355 cases and 7504 controls (Fig. 5; Supplementary Table 10). A
genetically predicted 1-SD decrease in FEV1 and FVC was not
associated with lung cancer risk in never smokers. However, a 10%
reduction in FEV1/FVC was associated with a 61% increased risk
(ORML= 1.61, 1.10–2.35, p= 0.014; ORIVW= 1.60, p= 0.030).
Outlier filtering did not have an appreciable impact on the results
(ORML= 1.56, 1.05–2.30, p= 0.027; ORIVW= 1.55, 1.05–2.28,
p= 0.028). A sensitivity analysis applied to 264 FEV1/FVC
instruments not specific to never smokers yielded an attenuated
estimate (ORIVW= 1.35, 1.03–1.75, p= 0.027), but confirmed the
impact of FEV1/FVC reduction on lung cancer risk.
For completeness, we also present MR estimates for the effect
of impaired pulmonary function on lung cancer risk in smokers
(Supplementary Table 11). Despite the larger sample size (23,223
cases and 16,964 controls) compared to never smokers, a
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genetically predicted 10% reduction in FEV1/FVC was weakly and
inconsistently associated with lung cancer risk (ORIVW= 1.15,
p= 0.038; ORRAPS= 1.08, p= 0.488). Genetic predisposition to
FEV1 and FVC impairment did not appear to confer an increased
risk among smokers.
Extensive MR diagnostics are summarized in Supplementary
Table 12. All analyses used strong instruments (F-statistic > 40)
and did not appear to be weakened by violations of the no
measurement error (NOME) assumption (I2GX statistic > 0.97).
MR Steiger test32 was used to orient the causal effects and
confirmed that instruments for pulmonary function were
affecting lung cancer susceptibility, not the reverse, and this
direction of effect was highly robust. No instruments were
removed based on Steiger filtering. We also confirmed that none
of the genetic instruments were associated with nicotine
dependence phenotypes (P < 1 × 10−5), such as time to first
cigarette, difficulty in quitting smoking, and number of quit
attempts, which were available for a subset of individuals in the
UKB. All MR analyses were adequately powered, with >80%
power to detect a minimum OR of 1.25 for FEV1 and FEV1/FVC
(Supplementary Fig. 2). For never smokers, we had 80% power to
detect a minimum OR of 1.40 for FEV1/FVC and 1.60 for FEV1.
Given the genetic correlation observed for pulmonary
phenotypes cigarette smoking and adiposity, we conducted
several sensitivity analyses to further address any potential
confounding by these phenotypes. The finding for squamous
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Fig. 4 Odds ratios (OR) and 95% confidence intervals for the effect of impaired pulmonary function on lung cancer risk, estimated using Mendelian
randomization (MR). Multiple MR estimation methods were applied to the International Lung Cancer Consortium OncoArray dataset, comprised of
29,266 lung cancer cases (11,273 adenocarcinoma, 7426 squamous cell carcinoma) and 56,450 controls to assess the causal relevance of impaired FEV1
(a), FVC (b), and FEV1/FVC (c). MR estimates based on the full set of genetic instruments are compared to estimates after excluding outliers suspected of
violating MR assumptions. Only associations with p-values < 0.25 are labeled. Proportion of variation explained by the genetic instruments was estimated
in a separate replication sample of over 110,000 individuals from the UK Biobank.
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Fig. 5 Scatterplot depicting the Mendelian randomization (MR) results for FEV1/FVC in never smokers and lung cancer in never smokers (2355 cases,
7504 controls). The scatterplot illustrates the effects of individual instruments on FEV1/FVC and lung cancer risk, highlighting potentially invalid outlier
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carcinoma and FEV1 was further interrogated using multivariable
MR (MVMR) by incorporating genetic instruments for BMI33
and smoking behavior34 to estimate the direct effect of FEV1 on
squamous carcinoma risk. MVMR using all instruments yielded
an OR of 1.95 (95% CI: 1.36–2.80, p= 2.8 × 10−4) per 1-SD
decrease in FEV1 and an OR of 1.63 (95% CI: 1.20–2.23, p=
1.8 × 10−3) after filtering outlier instruments.
We confirmed that none of the genetic instruments were
associated with smoking status (ever/never), cigarette pack-years
(continuous), or adiposity (body fat percentage) at the P < 5 ×
10–8 level. However, several variants were associated based on a P
< 1 × 10−5 threshold (25 for FEV1 and 18 for FEV1/FVC). We
repeated MR analyses after removing these variants (Supplemen-
tary Table 13) and confirmed that our results remained robust for
FEV1 and squamous cell carcinoma (ORIVW= 2.02, 1.40–2.92,
p= 1.9 × 10−4) and FEV1/FVC and adenocarcinoma (ORIVW=
1.19, 1.01–1.40, p= 0.04). However, there was still significant
heterogeneity among the causal effect estimates. After filtering the
remaining outliers, the effect of a 10% decrease in FEV1/FVC on
adenocarcinoma strengthened (ORIVW= 1.24, 1.08–1.43, p=
2.4 × 10−3), while estimates attenuated slightly for FEV1 and
squamous carcinoma (ORIVW= 1.46, 1.14–1.87, p= 2.7 × 10−3).
We also considered the possibility of residual confounding in
our GWAS due to insufficient adjustment for smoking-related
factors. We thus re-estimated SNP effects on FEV1, FVC, and
FEV1/FVC with adjustment for continuous cigarette pack-years
and years since quitting. The distribution of effect sizes did not
differ between the two analyses (p > 0.05), and the correlation
with our original instrument weights was strong for all
phenotypes (Pearson’s r ≥ 0.87, p < 1 × 10−40) (Supplementary
Fig. 3).
Last, we examined the association between FEV1 and FEV1/
FVC genetic instruments and COPD, defined as FEV1/FVC <
0.70. Among FEV1 instruments, 64% (123 variants) were
associated with COPD at p < 0.05 and 16% (31 variants) at p <
5 × 10−8 (Supplementary Fig. 4). All instruments for FEV1/FVC
were associated with COPD at the nominal level, and 40% (105
variants) reached genome-wide significance. Using weights from
estimated associations between the 105 instruments and COPD
log(OR), we observed a modestly increased risk of lung
adenocarcinoma (ORIVW= 1.08, 1.01–1.15, p= 0.015), which
parallels our findings based on instruments developed for the
continuous FEV1/FVC phenotype.
Functional characterization of lung function instruments. To
gain insight into biological mechanisms mediating the observed
effects of impaired pulmonary function on lung cancer risk, we
conducted in silico analyses of functional features associated with
the genetic instruments for each lung phenotype.
We identified 185 statistically significant (Bonferroni p < 0.05)
cis-eQTLs for 101 genes among the genetic instruments for FEV1
and FEV1/FVC based on lung tissue gene expression data from
the Laval biobank35 (Supplementary Data 7). Predicted expres-
sion of seven genes was significantly (p < 5.0 × 10−4) associated
with lung cancer risk: SECISBP2L, HLA-L, DISP2, MAPT,
KANSL1-AS1, LRRC37A4P, and PLEKHM1 (Supplementary
Fig. 5). Of these, SECISBP2L (OR= 0.80, p= 5.2 × 10−8), HLA-
L (OR= 0.84, p= 1.6 × 10−6), and DISP2 (OR= 1.25, p= 1.6 ×
10−4) displayed consistent directions of effect for pulmonary
function and lung cancer risk, whereby alleles associated with
increased expression were associated with impaired FEV1 or
FEV1/FVC and increased cancer risk (or conversely, positively
associated with pulmonary function and inversely associated with
cancer risk). Gene expression associations with inconsistent
effects are more likely to indicate pleiotropic pathways not
operating primarily through pulmonary impairment. Differences
by histology were observed for SECISBP2L, which was associated
with adenocarcinoma (OR= 0.54, p= 3.1 × 10−14), but not
squamous cell carcinoma (OR= 1.05, p= 0.44). Effects observed
for DISP2 (OR= 1.21, p= 0.021) and HLA-L (OR= 0.90, p=
0.034) were attenuated for adenocarcinoma, but not for
squamous carcinoma (DISP2: OR= 1.30, p= 6.2 × 10−3; HLA-
L: OR= 0.75, p= 1.6 × 10−6).
A total of 70 lung function instruments were mapped to
genome-wide significant (p < 5.0 × 10−8) protein quantitative trait
loci (pQTL) affecting the plasma levels of 64 different proteins
(Supplementary Data 8), based on data from the Human Plasma
Proteome Atlas36. Many of these pQTL targets are involved in
regulation of immune and inflammatory responses, such as
interleukins (IL21, IL1R1, IL17RD, IL18R1), MHC class I
polypeptide-related sequences, transmembrane glycoproteins
expressed by natural killer cells, and members of the tumor
necrosis receptor superfamily (TNFSF12, TNFRSF6B, TR19L).
Other notable associations include NAD(P)H dehydrogenase
[quinone] 1 (NQO1) a detoxification enzyme involved in
protecting lung tissues in response to reactive oxidative stress
(ROS) and promoting p53 stability37. NQO1 is a target of the
NFE2-related factor 2 (NRF2), a master regulator of cellular
antioxidant response that has generated considerable interest as a
chemoprevention target38,39.
Next, we analyzed genes where the lung function instruments
were localized using curated pathways from the Reactome
database. Significant enrichment (FDR q < 0.05) was observed
only for FEV1/FVC instruments in never smokers, with an over-
representation of pathways involved in adaptive immunity and
cytokine signaling (Supplementary Fig. 6). Top-ranking pathways
with q= 2.2 × 10−6 included translocation of ZAP-70 to
immunological synapse, phosphorylation of CD3 and TCR zeta
chains, and PD-1 signaling. These findings are in line with the
predominance of immune-related pQTL associations. Examining
all instruments for FEV1 and FEV1/FVC identified significant
over-representation (FDR q < 0.05) of six immunologic signatures
from the ImmuneSigDB collection40, including pathways impli-
cated in host response to infection and immunization (Supple-
mentary Fig. 7).
Discussion
Despite a substantial body of observational literature demon-
strating an increased risk of lung cancer in individuals with
pulmonary dysfunction2–7,41, confounding by shared environ-
mental risk factors and high co-occurrence of lung cancer and
airflow obstruction created uncertainty regarding the causal
nature of this relationship. We comprehensively investigated this
by characterizing shared genetic profiles between lung cancer and
lung function, and interrogated causal hypotheses using Mende-
lian randomization, which overcomes many limitations of
observational studies. We also provide insight into biological
pathways underlying the observed associations by incorporating
functional annotations into heritability analyses, assessing eQTL
and pQTL effects of lung function instruments, and conducting
pathway enrichment analyses.
The large sample size of the UK Biobank allowed us to suc-
cessfully create instruments for three pulmonary function phe-
notypes, FEV1, FEV1/FVC, and FVC. Although these phenotypes
are closely related, they capture different aspects of pulmonary
impairment, with FEV1 and FEV1/FVC used for diagnostic pur-
poses in clinical setting. Our genetic instruments captured known
and novel mechanisms involved in pulmonary function. Of the 73
novel variants identified here, many were in loci implicated in
immune-related functions and pathologies. Examples include
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HORMAD2, which has been previously linked to inflammatory
bowel disease42,43 and tonsillitis44, and RIPOR1 (also known as
FAM65A), which is part of a gene expression signature for
atopy45. PIEZO1 is primarily involved in mechano-transduction
and tissue differentiation during embryonic development46–48,
however, recent evidence has emerged delineating its role in
optimal T-cell receptor activation and immune regulation49.
BACH2, the new signal for FEV1/FVC in never smokers, is
involved in alveolar macrophage function50, as well as selection-
mediated TP53 regulation and checkpoint control51. The lead
variant identified here is independent (r2 < 0.05) of BACH2 loci
nominally associated with lung function decline in a candidate
gene study of COPD patients52, suggesting there may be differ-
ences in the genetic architecture of pulmonary traits in never
smokers.
Our genetic correlation analyses indicate shared genetic
determinants between pulmonary function with anthropometric
traits and cigarette smoking. Our results are in contrast with the
recent findings of Wyss et al.24, who did not observe statistically
significant genetic correlations for any pulmonary function phe-
notypes with height and smoking, as well FVC and FEV1/FVC,
using publicly available summary statistics from the UKB and
other studies of European ancestry individuals. In this respect,
assessing genetic correlation within a single well-characterized
population provides improved power while minimizing potential
for bias and heterogeneity when combining data from multiple
sources.
We observed statistically significant genetic correlations
between pulmonary function impairment and lung cancer sus-
ceptibility for all lung cancer subtypes, except for never smokers.
Reduced FEV1/FVC was significantly correlated with increased
risk of lung cancer overall, squamous cell carcinoma, and ade-
nocarcinoma. Significant genetic correlations with FEV1 and FVC
were observed for lung cancer overall, in smokers, and for tumors
with squamous cell histology, but not adenocarcinoma. Jiang
et al.25 reported a similar magnitude of genetic correlation with
FEV1/FVC, but did not observe an association with FVC, and did
not assess FEV1. Differences in our results may be attributable to
their use of GWAS summary statistics for pulmonary phenotypes
from the interim UK Biobank release. Our findings demonstrate
substantial overlap in the genetic architecture of obstructive and
neoplastic lung disease, particularly for highly conserved variants
that are likely to be subject to natural selection, and super
enhancers. However, genetic correlations do not support a causal
interpretation, especially considering the shared heritability with
potentially confounding traits, such as smoking and obesity.
On the other hand, Mendelian randomization analyses
revealed histology-specific effects of reduced FEV1 and FEV1/
FVC on lung cancer susceptibility, suggesting that these indica-
tors of impaired pulmonary function may be causal risk factors.
Genetic predisposition to FEV1 impairment conferred an
increased risk of lung cancer overall, particularly for squamous
carcinoma. This relationship persisted after filtering potentially
pleiotropic instruments and performing other sensitivity analyses,
including multivariable Mendelian randomization and manual
filtering of variants associated with smoking or adiposity. FEV1/
FVC reduction appeared to increase the risk of lung adeno-
carcinoma, as well as lung cancer among never smokers. The
latter finding is particularly compelling since it precludes con-
founding by smoking-related factors and demonstrates an asso-
ciation with the most clinically relevant pulmonary phenotype.
The increased lung cancer risk in never smokers was also
observed using genetic instruments developed specifically in
never smokers and in sensitivity analyses using instruments from
the population that also includes smokers. We hypothesize that
the effects of pulmonary obstruction are mediated by chronic
inflammation and immune response, which is supported by the
over-representation of adaptive immunity and cytokine signaling
pathways and pQTL effects among FEV1 and FEV1/FVC
instruments.
Examining lung eQTL effects of our genetic instruments
identified additional relevant mechanisms, including gene
expression of SECISBP2L and DISP2. SECISBP2L at 15q21 is
essential for ciliary function53 and has an inhibitory effect on lung
tumor growth by suppressing cell proliferation and inactivation of
Aurora kinase A54. This gene was among several susceptibility
regions identified in the most recent lung cancer GWAS16, and
now we more conclusively establish impaired pulmonary function
as the mechanism mediating SECISBP2L effects on risk of lung
cancer overall, particularly adenocarcinoma. Less is known about
DISP2, although it has been implicated in the conserved Hedge-
hog signaling pathway essential for embryonic development and
cell differentiation55.
One of the main challenges and outstanding questions in
previous epidemiologic studies has been clarifying how smoking
fits into the causal pathway between impaired pulmonary func-
tion and lung cancer risk. Are indicators of airway obstruction
simply proxies for smoking-induced carcinogenesis? The asso-
ciation between reduced FEV1/FVC and risk of adenocarcinoma
and lung cancer in never smokers observed in our Mendelian
randomization analysis and in previous studies8,9, argues against
this simplistic explanation and points to alternative pathways.
Chronic airway inflammation fosters a lung microenvironment
with altered signaling pathways, aberrant expression of cytokines,
chemokines, growth factors, and DNA damage-promoting agents,
all of which promote cancer initaiton15. This mechanism may be
particularly relevant for adenocarcinoma, which is the most
common lung cancer histology in never smokers, arising from the
peripheral alveolar epithelium that has less direct contact with
inhaled carcinogens.
Dysregulated immune function is a hallmark of lung cancer
and COPD, with both diseases sharing similar inflammatory cell
profiles characterized by macrophages, neutrophils, and CD4+
and CD8+ lymphocytes. Immune cells in COPD and emphysema
exhibit T helper 1 (Th1)/Th17 polarization, decreased pro-
grammed death ligand-1 (PD-L1) expression in alveolar macro-
phages, and increased production of interferon (IFN)-γ by CD8+
T cells56, a phenotype believed to prevail at tumor initiation,
whereas established tumors are dominated by Th2/M2-like
macrophages57. These putative mechanisms were highlighted in
our pathway analysis, with an enrichment of genes involved in
INF-γ, PD-1 and IL-1 signaling among FEV1/FVC genetic
instruments, and over-representation of pQTL targets in these
pathways. Furthermore, a study of trans-thoracically implanted
tumors in an emphysema mouse model demonstrates how this
pulmonary phenotype results in impaired antitumor T-cell
responses at a critical point when nascent cancer cells evade
detection and elimination by the immune system resulting in
enhanced tumor growth58.
Other relevant pathways implicating pulmonary dysfunction in
lung cancer development include lung tissue destruction via
matrix degrading enzymes and increased genotoxic and apoptotic
stress resulting from cigarette smoke in conjunction with mac-
rophage- and neutrophil-derived ROS15,59. This may explain our
findings for FEV1 and squamous carcinoma, for which cigarette
smoking is a particularly dominant risk factor. Genetic predis-
position to impaired FEV1 may create a milieu that promotes
malignant transformation and susceptibility to external carcino-
gens and tissue damage, rather than increasing the likelihood of
cigarette smoking. In our analysis we attempted to isolate the
former pathway from the latter by carefully instrumenting pul-
monary phenotypes and confirming that they are not associated
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with behavioral aspects of nicotine dependence. However, resi-
dual confounding by smoking cannot be entirely precluded, given
its high genetic and phenotypic correlation with FEV1.
The causal interpretation of our results critically depends on
the validity of fundamental Mendelian randomization assump-
tions. We employed a range of estimation techniques with dif-
ferent underlying assumptions, as well as diagnostic tests, to
interrogate the robustness of our results with respect to con-
founding, horizontal pleiotropy, and weak instrument bias.
However, despite these efforts, residual confounding by related
phenotypes, such as smoking, or subtle effects of population
structure cannot be ruled out. In evaluating the contribution of
our findings, several limitations should be acknowledged. Our
approach to outlier removal based on Cochran’s Q-statistic with
modified second order weights may have been overly stringent;
however, manually pruning based on such a large set of genetic
instruments may not be feasible and may introduce additional
bias, thus we feel this systematic conservative approach is justi-
fied. Furthermore, outlier removal did not have an adverse impact
on instrument strength and precision of the MR analysis.
In addition to pleiotropy, selection bias may also undermine
the validity of a Mendelian Randomization study, particularly in
the form of collider bias, if selection is a function of the exposure
or outcome. In the context of the UKB, low participation (5.5%)
may have resulted in an unrepresentative study population60,61.
Although enrollment in the cohort was not explicitly contingent
on cancer status or pulmonary function, it is likely that indivi-
duals who did not complete a spirometry assessment were more
likely to be smokers and have poor lung function. Simulations by
Gkatzionis and Burgess61 demonstrate that when the effect of a
risk factor on selection is mild to moderate (odds of selection:
0.82–0.61), the type I error rate remains reasonable at 5.0–6.6%.
The direction of the resulting bias depends on the direction and
strength of the exposure (lung function)–confounder (smoking)
relationship. In the context of our study, the causal effect may be
underestimated since the confounder and exposure are both likely
to increase non-participation or result in missing spirometry data.
Another limitation is that we did not assess the relationship
between the velocity of lung function decline and lung cancer
risk, which may also prove to be a risk factor and capture a
different dimension of pulmonary dysfunction. Furthermore,
since our study includes the largest GWAS of lung cancer cases in
never smokers, this precludes a well-powered replication study in
an independent European ancestry population. In addition,
dichotomous stratification by smoking status does not permit an
evaluation of the relationship between pulmonary impairment
and lung cancer risk across more granular levels of smoking. Last,
in our efforts to present the most comprehensive assessment of
pulmonary function impairment and lung cancer risk, a number
of analyses were conducted, and it may be possible that some
inconsistently observed associations were due to chance.
Despite these limitations, important strengths of this work
include the large sample size for instrument development and
causal hypothesis testing. Our Mendelian randomization
approach leveraged a large number of genetic instruments,
including variants specifically associated with lung function in
never smokers, while balancing the concerns related to genetic
confounding and pleiotropy. By triangulating evidence from gene
expression and plasma protein levels, we also provide a more
enriched interpretation of the genetic effects of pulmonary
function loci on lung cancer risk, which implicate immune-
mediated pathways. Despite the small individual SNP effect sizes,
combining multiple instruments revealed meaningful increases in
lung cancer risk. A genetically predicted 10% reduction in FEV1/
FVC confers an ~55% increased risk of lung cancer in never
smokers, and a similar magnitude of effect was observed for FEV1
and squamous carcinoma. However, effects of FEV1/FVC on
adenocarcinoma were more modest (16–23% increase). Taken
together, these findings provide more robust etiological insight
than previous studies that relied on using observed lung function
phenotypes directly as putatively casual factors.
As our understanding of the shared genetic and molecular
pathways between lung cancer and pulmonary disease continues
to evolve, identification of new susceptibility loci for pulmonary
function and lung cancer risk may have important implications
for future precision prevention and screening endeavors. Multiple
genetic determinants of lung function are in pathways that con-
tain druggable targets, based on our pQTL findings and previous
reports18, which may open new avenues for chemoprevention or
targeted therapies for lung cancers with an obstructive pulmonary
etiology. In addition, with accumulating evidence supporting the
effectiveness of low-dose computed tomography for lung can-
cer62,63, impairment in FEV1 and FEV1/FVC and their genetic
determinants may provide additional information for refining
risk stratification and screening eligibility criteria.
Methods
Study populations. The UK Biobank (UKB) is a population-based prospective
cohort of over 500,000 individuals aged 40–69 years at enrollment in 2006–2010
who completed extensive questionnaires on health-related factors, physical
assessments, and provided blood samples64. Participants were genotyped on the
UK Biobank Affymetrix Axiom array (89%) or the UK BiLEVE array (11%)64.
Genotype imputation was performed using the Haplotype Reference Consortium
data as the main reference panel as well as using the merged UK10K and 1000
Genomes (1000G) phase 3 reference panels64. Our analyses were restricted to
individuals of predominantly European ancestry based on self-report and after
excluding samples with either of the first two genetic ancestry principal compo-
nents (PCs) outside of 5 standard deviations (SD) of the population mean. Samples
with discordant self-reported and genetic sex were removed. Using a subset of
genotyped autosomal variants with minor allele frequency (MAF) ≥0.01 and call
rate ≥97%, we filtered samples with call rates <97% or heterozygosity >5 standard
deviations (SD) from the mean. First-degree relatives were identified using KING65
and one sample from each pair was excluded, leaving at total of 413,810 individuals
available for analysis.
We further excluded 36,461 individuals without spirometry data, 207
individuals who only completed one blow (n= 207), for whom reproducibility
could not be assessed (Supplementary Fig. 1). For the remaining subjects, we
examined the difference between the maximum value per individual (referred to as
the best measure) and all other blows. Values differing by more than 0.15 L were
considered non-reproducible, based on standard spirometry guidelines66, and were
excluded. Our analyses thus included 372,750 and 370,638 individuals for of FEV1
and FVC, respectively. The best per individual measure among the reproducible
blows was used to derive FEV1/FVC, resulting in 368,817 individuals. FEV1 and
FVC values were then converted to standardized Z-scores with a mean of 0 and
standard deviation (SD) of 1.
The OncoArray Lung Cancer study has been previously described16. Briefly,
this dataset consists of genome-wide summary statistics based on 29,266 lung
cancer cases (11,273 adenocarcinoma, 7426 squamous carcinoma) and 56,450
controls of predominantly European ancestry (≥80%) assembled from studies part
of the International Lung Cancer Consortium. Summary statistics from the lung
cancer GWAS were adjusted for appropriate covariates, including genetic ancestry
PCs, and showed no signs of genomic inflation for lung cancer overall (λGC=
1.0035) or for any subtypes, including adenocarcinoma (λGC= 1.0050), squamous
carcinoma (λGC= 1.0051), and lung cancer in never smokers (λGC= 1.0060).
Informed consent was obtained from study participants in the UK Biobank and
studies contributing data to the OncoArray Lung Cancer collaboration. UK
Biobank received ethics approval from the Research Ethics Committee (REC
reference: 11/NW/0382). Approval for OncoArray studies was obtained from each
of the participating institutional research ethics review boards.
Genome-wide association analysis. Genome-wide association analyses of pul-
monary function phenotypes in the UK Biobank cohort were conducted using
PLINK 2.0 (October 2017 version). We excluded variants out of with
Hardy–Weinberg equilibrium at p < 1 × 10−5 in cancer-free individuals, call rate
<95% (alternate allele dosage required to be within 0.1 of the nearest hard call to be
non-missing), imputation quality INFO < 0.30, and MAF < 0.005. To minimize
potential for reverse causation, prevalent lung cancer cases, defined as diagnoses
occurring up to 5 years before cohort entry and incident cases occurring within 2
years of enrollment, were excluded (n= 738). Linear regression models for pul-
monary function phenotypes (standardized Z-scores for FEV1 and FVC;
untransformed FEV1/FVC ratio bounded by 0 and 1) were adjusted for age, age2,
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sex, genotyping array and 15 PCs to permit an assessment of heritability (hg) and
genetic correlation (rg) with height, smoking (status and pack-years), and
anthropometric traits.
Heritability and genetic correlation. LD Score regression17 was used to estimate
hg for each lung phenotype and rg with lung cancer and other traits. To better
capture LD patterns present in the UKB data, we generated LD scores for all
variants that passed QC with MAF > 0.0001 using a random sample of 10,000 UKB
participants. UKB LD scores were used to estimate hg for each lung phenotype and
rg with other non-cancer traits. Genetic correlation with lung cancer was estimated
using publicly available LD scores based on the 1000G phase 3 reference population
(n= 1,095,408 variants).
To assess the importance of specific functional annotations in SNP-heritability,
we partitioned trait-specific heritability using stratified-LDSC67. The analysis was
performed using 86 annotations (baseline-LD model v2.1), which incorporated
MAF-adjustment and other LD-related annotations, such as predicted allele age
and recombination rate20,22. The MHC region was excluded from partitioned
heritability analyses. Enrichment was considered statistically significant if p < 8.5 ×
10−4, which reflects Bonferroni correction for 59 annotations (functional categories
with and without a 500 bp window around it were considered as the same
annotation).
Development of genetic instruments for pulmonary function. For the purpose of
instrument development, a two-stage genome-wide analysis was employed, with a
randomly sampled 70% of the cohort used for discovery and the remaining 30%
reserved for replication. In addition to age, age2, sex, genotyping array and 15 PC’s,
models were adjusted for covariates that explain a substantial proportion of variation
in pulmonary phenotypes, such as smoking and height, in order to decrease the
residual variance and help isolate the relevant genetic signals. Specifically, we adjusted
for height, height2, and cigarette pack-year categories (0, corresponding to never
smokers, >0–10, >10–20, >20–30, >30–40, and >40). Other covariates, such as UKB
assessment center (Field 54), use of an inhaler prior to spirometry (Field 3090), and
blow acceptability (Field 3061) were considered. However, these covariates did not
explain a substantial proportion of phenotype variation and had low variable
importance metrics (lmg < 0.01), and thus were not included in our final models.
Instruments were selected from independent associated variants (LD r2 < 0.05 in a
clumping window of 10,000 kb) with P < 5 × 10−8 in the discovery stage and P < 0.05
and consistent direction of effect in the replication stage. Since the primary goal of our
GWAS was to develop a comprehensive set of genetic instruments we applied a less
stringent replication threshold in anticipation of subsequent filtering based on
potential violation of Mendelian randomization assumptions.
Mendelian randomization. Mendelian randomization (MR) analyses were carried
out to investigate the potential causal relationship between impaired pulmonary
function and lung cancer risk. Genetic instruments excluded multi-allelic and non-
inferable palindromic variants with intermediate allele frequencies (MAF > 0.42).
Odds ratios (OR) and corresponding 95% confidence intervals were obtained using
the maximum likelihood and inverse variance weighted multiplicative random-
effects (IVW-RE) estimators28,29. Effects for FEV1 and FVC were estimated for a
genetically predicted 1-SD decrease in the standardized Z-score. For FEV1/FVC, we
modeled cancer risk corresponding to a 10% decrease in the ratio. Sensitivity
analyses included the weighted median (WM) estimator30, which provides
unbiased estimates when up to 50% of the weights are from invalid instruments,
and MR RAPS (Robust Adjusted Profile Score), which incorporates random effect
and robust loss functions to limit the influence of potentially pleiotropic instru-
ments. MR RAPS assumes balanced (mean 0) horizontal pleiotropy. In contrast to
IVW-RE, MR RAPS models idiosyncratic and systematic pleiotropy effects as
additive, rather than multiplicative31. Using MR estimation techniques with dif-
ferent underlying statistical models allows for a more comprehensive assessment of
the robustness of our results with respect to violations of MR assumptions. We also
applied the following diagnostic tests: (i) significant (p < 0.05) deviation of the MR
Egger intercept (β0 Egger) from 0, as a test for directional pleiotropy68; (ii) I2GX
statistic < 0.90 indicative of regression dilution bias and inflation in the MR Egger
pleiotropy test due to violation of the no measurement error (NOME) assump-
tion68; (iii) Cochran’s Q-statistic with modified second order weights to asses
heterogeneity (p-value < 0.05) indicative of (balanced) horizontal pleiotropy69.
All statistical analyses were conducted using R (version 3.6.1). Mendelian
randomization analyses were conducted using the TwoSampleMR R package
(version 0.4.23).
Functional characterization of lung function instruments. In order to char-
acterize functional pathways that are represented by the genetic instruments for
FEV1 and FEV1/FVC, we examined effects on gene expression in lung tissues from
409 subjects from the Laval eQTL study35. Lung function instruments with sig-
nificant (Bonferroni p-value < 0.05) eQTL effects were used as instruments to
estimate the effect of the gene expression on lung cancer risk. For genes with
multiple eQTLs, independent variants (LD r2 < 0.05) were used to obtain IVW
estimates of the predicted effects of increased gene expression on lung cancer risk.
For genes with a single eQTL, OR estimates were obtained using the Wald method.
Next, we examined data from the genetic atlas of the human plasma proteome36,
queried using PhenoScanner70, to assess whether any of the genetic instruments for
FEV1 and FEV1/FVC had significant (p < 5 × 10−8) effects on intracellular protein
levels. Last, we summarized the pathways represented by the genes where the lung
function instruments were localized using pathway enrichment analysis via the
Reactome database and ImmuneSigDB (collection C7 from MSigDB).
URLs. PLINK 2.0: https://www.cog-genomics.org/plink/2.0/
LDSC (version 1.0.0) from: https://github.com/bulik/ldsc/
LDSC functional annotations available from:
https://data.broadinstitute.org/alkesgroup/LDSCORE/1000G_Phase3_EUR_base
lineLD_v2.1_ldscores.tgz
R package for Circos plots (version 0.4.7): https://github.com/jokergoo/circlize
R package for Mendelian Randomization (version 0.4.23): https://github.com/
MRCIEU/TwoSampleMR
R package for PhenoScanner (version 1.0): https://github.com/phenoscanner/
phenoscanner
R packages for pathway analysis: https://bioconductor.org/packages/release/
bioc/html/ReactomePA.html and https://bioconductor.org/packages/release/bioc/
html/clusterProfiler.html
ImmuneSigDB (C7): http://software.broadinstitute.org/gsea/msigdb/collections.
jsp.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The datasets generated during and/or analyzed during the current study are available
from the authors on request. Genotype data for the Oncoarray Consortium Lung Cancer
studies have been deposited in the database of Genotypes and Phenotypes (dbGaP) under
accession: phs001273.v2.p2. Readers interested in obtaining a copy of the lung cancer
GWAS summary statistics can do so by completing the proposal request form at http://
oncoarray.dartmouth.edu/. The UK Biobank in an open access resource, available at
https://www.ukbiobank.ac.uk/researchers/. This research was conducted with approved
access to UK Biobank data under applications number 14105 and 23261. All data
supporting the findings of this study are available within the article and its
supplementary information files, and from the corresponding authors upon reasonable
request. A reporting summary for this article is available as a Supplementary file.
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